These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30205105)

  • 21. Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta-analysis of urodynamic studies.
    Fusco F; Creta M; De Nunzio C; Gacci M; Li Marzi V; Finazzi Agrò E
    Neurourol Urodyn; 2018 Aug; 37(6):1865-1874. PubMed ID: 29603785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Change of Ultrasound Estimated Bladder Weight and Bladder Wall Thickness After Treatment of Bladder Outlet Obstruction With Dutasteride.
    Lee HN; Lee YS; Han DH; Lee KS
    Low Urin Tract Symptoms; 2017 May; 9(2):67-74. PubMed ID: 28394496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic.
    Hanuš T; Zámečník L; Doležal T; Karmazínová Z
    Urol Int; 2011; 86(4):407-13. PubMed ID: 21454947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Male lower urinary tract symptoms: treatment with a-blockers, 5-a-reductase inhibitors, antimuscarinics, or a combination.
    Appell RA
    Curr Urol Rep; 2007 Sep; 8(5):370-2. PubMed ID: 17880835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia].
    Höfner K; Bach T; Berges R; Dreikorn K; Gratzke C; Madersbacher S; Michel MS; Muschter R; Oelke M; Reich O; Tschuschke C; Bschleipfer T
    Urologe A; 2016 Feb; 55(2):184-94. PubMed ID: 26518303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review.
    Kaplan SA; Roehrborn CG; Abrams P; Chapple CR; Bavendam T; Guan Z
    Int J Clin Pract; 2011 Apr; 65(4):487-507. PubMed ID: 21210910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
    Sarma AV; Wei JT
    N Engl J Med; 2012 Jul; 367(3):248-57. PubMed ID: 22808960
    [No Abstract]   [Full Text] [Related]  

  • 29. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
    Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
    Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
    Mudiyala R; Ahmed A
    J Am Geriatr Soc; 2003 Mar; 51(3):424-6. PubMed ID: 12588590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.
    Jhang JF; Liao CH; Kuo HC
    Int J Clin Pract; 2014 Jun; 68(6):743-8. PubMed ID: 24471413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Benign prostate hyperplasia: success and limitations of pharmacological therapy].
    Madersbacher S; Marszalek M
    Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant?
    Smith AL; Wein AJ
    BJU Int; 2011 May; 107(10):1550-4. PubMed ID: 21518417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
    Roehrborn CG
    Med Clin North Am; 2011 Jan; 95(1):87-100. PubMed ID: 21095413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis.
    Lenfant L; Pinar U; Roupret M; Mozer P; Chartier-Kastler E; Seisen T
    J Urol; 2023 Feb; 209(2):314-324. PubMed ID: 36395428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.